SpringerLink
Log in

Multidrug-Resistant Organisms in Solid Organ Transplantation

  • Chapter
  • First Online:
Infectious Diseases in Solid-Organ Transplant Recipients

Abstract

Despite advances in the field of solid organ transplantation (SOT), multidrug-resistant (MDR) bacterial infections are responsible for significant morbidity and mortality worldwide. The most common MDR Gram-positive bacteria include methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). Therapeutic options exist for both MRSA and VRE infections, and MRSA infections appear to be declining. However, infections with MDR Gram-negative bacteria, specifically with Enterobacteriaceae, Pseudomonas, and Acinetobacter, continue to pose a significant threat to SOT recipients. Increasing attention should be focused on prevention and optimal management of infections with these organisms. Although several new therapeutic options exist, the importance of source control, infection prevention, and antimicrobial stewardship should always be emphasized.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268–81.

    Article  CAS  PubMed  Google Scholar 

  2. Kaye KS, Pogue JM. Infections caused by resistant Gram-negative bacteria: epidemiology and management. Pharmacotherapy. 2015;35:949–62.

    Article  CAS  PubMed  Google Scholar 

  3. Calfee DP. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci, and other Gram-positives in healthcare. Curr Opin Infect Dis. 2012;25:385–94.

    Article  CAS  PubMed  Google Scholar 

  4. Weiner LM, Fridkin SK, Aponte-Torres Z, et al. Vital signs: preventing antibiotic-resistant infections in hospitals – United States, 2014. Am J Transplant. 2016;16:2224–30.

    Article  CAS  PubMed  Google Scholar 

  5. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis. 2003;36:53–9.

    Article  PubMed  Google Scholar 

  6. Engemann JJ, Carmeli Y, Cosgrove SE, Fowler VG, Bronstein MZ, Trivette SL, Briggs JP, Sexton DJ, Kaye KS. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis. 2003;36:592–8.

    Article  PubMed  Google Scholar 

  7. Garzoni C, Vergidis P. Methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus infections in solid organ transplantation. Am J Transplant. 2013;13:50–8.

    Article  CAS  PubMed  Google Scholar 

  8. Wendt JM, Kaul D, Limbago BM, et al. Transmission of methicillin-resistant Staphylococcus aureus infection through solid organ transplantation: confirmation via whole genome sequencing. Am J Transplant. 2014;14:2633–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Altman DR, Sebra R, Hand J, et al. Transmission of methicillin-resistant Staphylococcus aureus via deceased donor liver transplantation confirmed by whole genome sequencing. Am J Transplant. 2014;14:2640–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Florescu DF, McCartney AM, Qiu F, Langnas AN, Botha J, Mercer DF, Grant W, Kalil AC. Staphylococcus aureus infections after liver transplantation. Infection. 2012;40:263–9.

    Article  CAS  PubMed  Google Scholar 

  11. Singh N, Paterson DL, Chang FY, Gayowski T, Squier C, Wagener MM, Marino IR. Methicillin-resistant Staphylococcus aureus: the other emerging resistant Gram-positive coccus among liver transplant recipients. Clin Infect Dis. 2000;30:322–7.

    Article  CAS  PubMed  Google Scholar 

  12. Schneider CR, Buell JF, Gearhart M, Thomas M, Hanaway MJ, Rudich SM, Woodle ES. Methicillin-resistant Staphylococcus aureus infection in liver transplantation: a matched controlled study. Transplant Proc. 2005;37(2):1243–4.

    Article  CAS  PubMed  Google Scholar 

  13. Bert F, Bellier C, Lassel L, Lefranc V, Durand F, Belghiti J, Mentre F, Fantin B. Risk factors for Staphylococcus aureus infection in liver transplant recipients. Liver Transpl. 2005;11:1093–9.

    Article  PubMed  Google Scholar 

  14. Shields RK, Clancy CJ, Minces LR, et al. Staphylococcus aureus infections in the early period after lung transplantation: epidemiology, risk factors, and outcomes. J Heart Lung Transplant. 2012;31:1199–206.

    Article  PubMed  Google Scholar 

  15. Russell DL, Flood A, Zaroda TE, Acosta C, Riley MMS, Busuttil RW, Pegues DA. Outcomes of colonization with MRSA and VRE among liver transplant candidates and recipients. Am J Transplant. 2008;8:1737–43.

    Article  CAS  PubMed  Google Scholar 

  16. Ziakas PD, Pliakos EE, Zervou FN, Knoll BM, Rice LB, Mylonakis E. MRSA and VRE colonization in solid organ transplantation: a meta-analysis of published studies. Am J Transplant. 2014;14:1887–94.

    Article  CAS  PubMed  Google Scholar 

  17. Holmes NE, Tong SYC, Davis JS, Van Hal SJ. Treatment of methicillin-resistant Staphylococcus aureus: vancomycin and beyond. Semin Respir Crit Care Med. 2015;36:17–30.

    Article  PubMed  Google Scholar 

  18. Choo EJ, Chambers HF. Treatment of methicillin-resistant Staphylococcus aureus bacteremia. Infect Chemother. 2016;48:267–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Gudiol C, Cuervo G, Shaw E, Pujol M, Carratalà J. Pharmacotherapeutic options for treating Staphylococcus aureus bacteremia. Expert Opin Pharmacother. 2017;6566:1–17.

    Google Scholar 

  20. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011. https://doi.org/10.1093/cid/ciq146

    Article  PubMed  Google Scholar 

  21. Van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis. 2012;54:755–71.

    Article  PubMed  CAS  Google Scholar 

  22. Kalil AC, Van Schooneveld TC, Fey PD, Rupp ME. Association between vancomycin minimum inhibitory concentration and mortality among patients with Staphylococcus aureus bloodstream infections: a systematic review and meta-analysis. JAMA. 2014;312:1552–64.

    Article  PubMed  CAS  Google Scholar 

  23. Purrello SM, Garau J, Giamarellos E, Mazzei T, Pea F, Soriano A, Stefani S. Methicillin-resistant Staphylococcus aureus infections: a review of the currently available treatment options. J Glob Antimicrob Resist. 2016;7:178–86.

    Article  CAS  PubMed  Google Scholar 

  24. Edwards B, Andini R, Esposito S, Grossi P, Lew D, Mazzei T, Novelli A, Soriano A, Gould IM. Treatment options for methicillin-resistant Staphylococcus aureus (MRSA) infection: where are we now? J Glob Antimicrob Resist. 2014;2:133–40.

    Article  CAS  PubMed  Google Scholar 

  25. Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, McGee WT, Reisman A, Chastre J. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis. 2012;54:621–9.

    Article  CAS  PubMed  Google Scholar 

  26. Swartz TH, Huprikar S, Labombardi V, Pinney S, Anyanwu A, Lee M, Patel G. Heart transplantation in a patient with heteroresistant vancomycin-intermediate Staphylococcus aureus ventricular assist device mediastinitis and bacteremia. Transpl Infect Dis. 2013. https://doi.org/10.1111/tid.12123

  27. Bert F, Clarissou J, Durand F, Delefosse D, Chauvet C, Lefebvre P, Lambert N, Branger C. Prevalence, molecular epidemiology, and clinical significance of heterogeneous glycopeptide-intermediate Staphylococcus aureus in liver transplant recipients. J Clin Microbiol. 2003;41:5147–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Singh N, Squier C, Wannstedt C, Keyes L, Wagener MM, Cacciarelli TV. Impact of an aggressive infection control strategy on endemic Staphylococcus aureus infection in liver transplant recipients. Infect Control Hosp Epidemiol. 2006;27:122–6.

    Article  PubMed  Google Scholar 

  29. Climo MW, Yokoe DS, Warren DK, et al. Effect of daily chlorhexidine bathing on hospital-acquired infection. N Engl J Med. 2013;368:533–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Pergam SA. Infection prevention in transplantation. Curr Infect Dis Rep. 2016;18:1–10.

    Article  Google Scholar 

  31. Hand J, Patel G. Multidrug-resistant organisms in liver transplant: mitigating risk and managing infections. Liver Transpl. 2016;22:1143–53.

    Article  PubMed  Google Scholar 

  32. Patel G, Snydman DR. Vancomycin-resistant Enterococcus infections in solid organ transplantation. Am J Transplant. 2013;13:59–67.

    Article  CAS  PubMed  Google Scholar 

  33. McNeil SA, Malani PN, Chenoweth CE, Fontana RJ, Magee JC, Punch JD, Mackin ML, Kauffman CA. Vancomycin-resistant enterococcal colonization and infection in liver transplant candidates and recipients: a prospective surveillance study. Clin Infect Dis. 2006;42:195–203.

    Article  PubMed  Google Scholar 

  34. Newell KA, Millis JM, Arnow PM, et al. Incidence and outcome of infection by vancomycin-resistant Enterococcus following orthotopic liver transplantation. Transplantation. 1998;65:439–42.

    Article  CAS  PubMed  Google Scholar 

  35. Gearhart M, Martin J, Rudich S, et al. Consequences of vancomycin-resistant Enterococcus in liver transplant recipients: a matched control study. Clin Transpl. 2005;19:711–6.

    Google Scholar 

  36. El-Khoury J, Fishman JA. Linezolid in the treatment of vancomycin-resistant Enterococcus faecium in solid organ transplant recipients: report of a multicenter compassionate-use trial. Transpl Infect Dis. 2003;5:121–5.

    Article  CAS  PubMed  Google Scholar 

  37. Radunz S, Juntermanns B, Kaiser GM, Treckmann J, Mathe Z, Paul A, Saner FH. Efficacy and safety of linezolid in liver transplant patients. Transpl Infect Dis. 2011;13:353–8.

    Article  CAS  PubMed  Google Scholar 

  38. Kohinke RM, Pakyz AL. Treatment of vancomycin-resistant Enterococci: focus on daptomycin. Curr Infect Dis Rep. 2017;19(10):33. https://doi.org/10.1007/s11908-017-0589-2.

    Article  PubMed  Google Scholar 

  39. Len O, Montejo M, Cervera C, et al. Daptomycin is safe and effective for the treatment of Gram-positive cocci infections in solid organ transplantation. Transpl Infect Dis. 2014;16:532–8.

    Article  CAS  PubMed  Google Scholar 

  40. Britt NS, Potter EM, Patel N, Steed ME. Comparative effectiveness and safety of standard-, medium-, and high-dose daptomycin strategies for the treatment of vancomycin-resistant enterococcal bacteremia among veterans affairs patients. Clin Infect Dis. 2017;64:605–13.

    CAS  PubMed  Google Scholar 

  41. Chuang YC, Lin HY, Chen PY, Lin CY, Wang JT, Chang SC. Daptomycin versus linezolid for the treatment of vancomycin-resistant enterococcal bacteraemia: implications of daptomycin dose. Clin Microbiol Infect. 2016;22:890.e1–7.

    Article  CAS  Google Scholar 

  42. Sierra-Hoffman M, Iznaola O, Goodwin M, Mohr J. Combination therapy with ampicillin and daptomycin for treatment of Enterococcus faecalis endocarditis. Antimicrob Agents Chemother. 2012;56:6064.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Snyder AH, Werth BJ, Barber KE, Sakoulas G, Rybak MJ. Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model. J Antimicrob Chemother. 2014;69:2148–54.

    Article  CAS  Google Scholar 

  44. Smith JR, Barber KE, Raut A, Aboutaleb M, Sakoulas G, Rybak MJ. β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium. J Antimicrob Chemother. 2014;70:1738–43.

    Google Scholar 

  45. Lewis JD, Enfield KB, Cox HL, Mathers AJ, Sifri CD. A single-center experience with infections due to daptomycin-nonsusceptible Enterococcus faecium in liver transplant recipients. Transpl Infect Dis. 2016;18:341–53.

    Article  CAS  PubMed  Google Scholar 

  46. Niebel M, Perera MTPR, Shah T, Marudanayagam R, Martin K, Oppenheim BA, David MD. Emergence of linezolid resistance in hepatobiliary infections caused by Enterococcus faecium. Liver Transpl. 2016;22:201–8.

    Article  PubMed  Google Scholar 

  47. Banach DB, Peaper DR, Fortune BE, Emre S, Dembry LM. The clinical and molecular epidemiology of pre-transplant vancomycin-resistant enterococci colonization among liver transplant recipients. Clin Transpl. 2016;30:306–11.

    Article  Google Scholar 

  48. Cheng VCC, Chen JHK, Tai JWM, et al. Decolonization of gastrointestinal carriage of vancomycin-resistant Enterococcus faecium: case series and review of literature. BMC Infect Dis. 2014;14:514.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Pouch SM, Satlin MJ. Carbapenem-resistant Enterobacteriaceae in special populations: solid organ transplant recipients, stem cell transplant recipients, and patients with hematologic malignancies. Virulence. 2017;8:391–402.

    Article  CAS  PubMed  Google Scholar 

  50. Satlin MJ, Jenkins SG, Walsh TJ. The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies. Clin Infect Dis. 2014;58:1274–83.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  51. Giani T, Conte V, Mandalà S, D’Andrea MM, Luzzaro F, Conaldi PG, Grossi P, Rossolinia GM. Cross-infection of solid organ transplant recipients by a multidrug-resistant Klebsiella pneumoniae isolate producing the OXA-48 carbapenemase, likely derived from a multiorgan donor. J Clin Microbiol. 2014;52:2702–5.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Grundmann H, Glasner C, Albiger B, et al. Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. Lancet Infect Dis. 2017;17:153–63.

    Article  CAS  PubMed  Google Scholar 

  53. CDC. Antibiotic resistance threats in the United States, 2013 | Antibiotic/Antimicrobial Resistance | CDC; 2013.

    Google Scholar 

  54. Van Duin D, Van Delden C. Multidrug-resistant Gram-negative bacteria infections in solid organ transplantation. Am J Transplant. 2013;13:31–41.

    Article  PubMed  CAS  Google Scholar 

  55. Rana MM, Sturdevant M, Patel G, Huprikar S. Klebsiella necrotizing soft tissue infections in liver transplant recipients: a case series. Transpl Infect Dis. 2013. https://doi.org/10.1111/tid.12103

    Article  CAS  PubMed  Google Scholar 

  56. Lübbert C, Becker-Rux D, Rodloff AC, Laudi S, Busch T, Bartels M, Kaisers UX. Colonization of liver transplant recipients with KPC-producing Klebsiella pneumoniae is associated with high infection rates and excess mortality: a case-control analysis. Infection. 2014;42:309–16.

    Article  PubMed  Google Scholar 

  57. Kalpoe JS, Sonnenberg E, Factor SH, del Rio Martin J, Schiano T, Patel G, Huprikar S. Mortality associated with carbapenem-resistant Klebsiella pneumoniae infections in liver transplant recipients. Liver Transpl. 2012;18:468–74.

    Article  PubMed  Google Scholar 

  58. Barchiesi F, Montalti R, Castelli P, Nicolini D, Staffolani S, Mocchegiani F, Fiorentini A, Manso E, Vivarelli M. Carbapenem-resistant Klebsiella pneumoniae influences the outcome of early infections in liver transplant recipients. BMC Infect Dis. 2016;16:538.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae Infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol. 2008;29:1099–106.

    Article  PubMed  Google Scholar 

  60. Freire MP, Oshiro ICVS, Pierrotti LC, et al. Carbapenem-resistant Enterobacteriaceae acquired before liver transplantation. Transplantation. 2017;101:811–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Pereira MR, Scully BF, Pouch SM, Uhlemann A-C, Goudie S, Emond JE, Verna EC. Risk factors and outcomes of carbapenem-resistant Klebsiella pneumoniae infections in liver transplant recipients. Liver Transpl. 2015;21:1511–9.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Giannella M, Bartoletti M, Morelli MC, et al. Risk factors for infection with carbapenem-resistant Klebsiella pneumoniae after liver transplantation: the importance of pre- and posttransplant colonization. Am J Transplant. 2015;15:1708–15.

    Article  CAS  PubMed  Google Scholar 

  63. Freire MP, Abdala E, Moura ML, de Paula FJ, Spadão F, Caiaffa-Filho HH, David-Neto E, Nahas WC, Pierrotti LC. Risk factors and outcome of infections with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in kidney transplant recipients. Infection. 2015;43:315–23.

    Article  CAS  PubMed  Google Scholar 

  64. Pouch SM, Kubin CJ, Satlin MJ, Tsapepas DS, Lee JR, Dube G, Pereira MR. Epidemiology and outcomes of carbapenem-resistant Klebsiella pneumoniae bacteriuria in kidney transplant recipients. Transpl Infect Dis. 2015. https://doi.org/10.1111/tid.12450

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Freire MP, Villela Soares Oshiro IC, Bonazzi PR, et al. Surveillance culture for multidrug-resistant Gram-negative bacteria: performance in liver transplant recipients. Am J Infect Control. 2017;45:e40–4.

    Article  PubMed  Google Scholar 

  66. Huprikar S, Casner L, Pierrotti LC, Nellore A, Madan R, Garcia-Diaz J, Jacobs S, Lee D, Trindade Clemente W, Alangaden G Outcomes associated with carbapenem-resistant Enterobacteriaceae infection after solid organ transplantation in a multicenter study. Progr. Abstr. 16th Am. Transpl. Congr. Am. Soc. Transpl. Surg. Am. Soc. Transplantation, Boston, MA; 2016.

    Google Scholar 

  67. Ariza-Heredia EJ, Patel R, Blumberg EA, et al. Outcomes of transplantation using organs from a donor infected with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae. Transpl Infect Dis. 2012;14:229–36.

    Article  CAS  PubMed  Google Scholar 

  68. van Duin D, Bonomo RA. Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation β-lactam/β-lactamase inhibitor combinations. Clin Infect Dis. 2016;63:234–41.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  69. Falagas ME, Mavroudis AD, Vardakas KZ. The antibiotic pipeline for multi-drug resistant Gram negative bacteria: what can we expect? Expert Rev Anti-Infect Ther. 2016;14:747–63.

    Article  CAS  PubMed  Google Scholar 

  70. Wright H, Bonomo RA, Paterson DL. New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn? Clin Microbiol Infect. 2017;23:704–12.

    Article  CAS  PubMed  Google Scholar 

  71. Vardakas KZ, Falagas ME. Colistin versus polymyxin B for the treatment of patients with multidrug-resistant Gram-negative infections: a systematic review and meta-analysis. Int J Antimicrob Agents. 2017;49:233–8.

    Article  CAS  PubMed  Google Scholar 

  72. Mills JP, Wilck MB, Weikert BC, Porrett PM, Timko D, Alby K, Bonomo RA, Blumberg EA. Successful treatment of a disseminated infection with extensively drug-resistant Klebsiella pneumoniae in a liver transplant recipient with a fosfomycin-based multidrug regimen. Transpl Infect Dis. 2016;18:777–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55:943–50.

    Article  CAS  PubMed  Google Scholar 

  74. Bonomo RA, Burd EM, Conly J, Limbago BM, Poirel L, Segre JA. Carbapenemase-producing organisms: a global scourge! Clin Infect Dis. 2017;66:1290–7.

    Article  PubMed Central  CAS  Google Scholar 

  75. Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis. 2017;17:726–34.

    Article  PubMed  Google Scholar 

  76. van Duin D, Lok JJ, Earley M, et al. Colistin vs. ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis. 2017. https://doi.org/10.1093/cid/cix783

    Article  PubMed Central  Google Scholar 

  77. Shields RK, Nguyen MH, Chen L, Press EG, Potoski BA, Marini R V., Doi Y, Kreiswirth BN, Clancy CJ. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother. 2017. https://doi.org/10.1128/AAC.00883-17

  78. King M, Heil E, Kuriakose S, et al. Multicenter study of outcomes with ceftazidime-avibactam in patients with carbapenem-resistant Enterobacteriaceae infections. Antimicrob Agents Chemother. 2017. https://doi.org/10.1128/AAC.00449-17

    Google Scholar 

  79. Humphries RM, Yang S, Hemarajata P, Ward KW, Hindler JA, Miller SA, Gregson A. First report of ceftazidime-avibactam resistance in a KPC-3-expressing Klebsiella pneumoniae isolate. Antimicrob Agents Chemother. 2015;59:6605–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Centers for Disease Control and Prevention (CDC). Facility guidance for control of carbapenem-resistant Enterobacteriaceae (CRE). Natl Cent Emerg Zoonotic Infect Dis. 2015;24:700–9.

    Google Scholar 

  81. Arizpe A, Reveles KR, Patel SD, Aitken SL. Updates in the management of cephalosporin-resistant Gram-negative bacteria. Curr Infect Dis Rep. 2016. https://doi.org/10.1007/s11908-016-0552-7

  82. Aguado JM, Silva JT, Fernández-Ruiz M, et al. Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations. Transplant Rev. 2017. https://doi.org/10.1016/j.trre.2017.07.001

    Article  CAS  PubMed  Google Scholar 

  83. Cervera C, van Delden C, Gavaldà J, Welte T, Akova M, Carratalà J. Multidrug-resistant bacteria in solid organ transplant recipients. Clin Microbiol Infect. 2014;20(Suppl 7):49–73.

    Article  PubMed  Google Scholar 

  84. Johnson LE, D’Agata EMC, Paterson DL, Clarke L, Qureshi ZA, Potoski BA, Peleg AY. Pseudomonas aeruginosa bacteremia over a 10-year period: multidrug resistance and outcomes in transplant recipients. Transpl Infect Dis. 2009;11:227–34.

    Article  CAS  PubMed  Google Scholar 

  85. Dobbin C, Maley M, Harkness J, Benn R, Malouf M, Glanville A, Bye P. The impact of pan-resistant bacterial pathogens on survival after lung transplantation in cystic fibrosis: results from a single large referral centre. J Hosp Infect. 2004;56:277–82.

    Article  CAS  PubMed  Google Scholar 

  86. Hadjiliadis D, Steele MP, Chaparro C, Singer LG, Waddell TK, Hutcheon MA, Davis RD, Tullis DE, Palmer SM, Keshavjee S. Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other than Burkholderia cepacia, compared with patients harboring sensitive bacteria. J Hear Lung Transplant. 2007;26:834–8.

    Article  Google Scholar 

  87. Bodro M, Sabe N, Tubau F, Llado L, Baliellas C, Gonzalez-Costello J, Cruzado JM, Carratala J. Extensively drug-resistant Pseudomonas aeruginosa bacteremia in solid organ transplant recipients. Transplantation. 2015;99:616–22.

    Article  CAS  PubMed  Google Scholar 

  88. Wenzler E, Fraidenburg DR, Scardina T, Danziger LH. Inhaled antibiotics for Gram-negative respiratory infections. Clin Microbiol Rev. 2016;29:581–632.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Maraolo AE, Cascella M, Corcione S, Cuomo A, Nappa S, Borgia G, De Rosa FG, Gentile I. Management of multidrug-resistant Pseudomonas aeruginosa in the intensive care unit: state of the art. Expert Rev Anti-Infect Ther. 2017;15:861–71.

    Article  CAS  PubMed  Google Scholar 

  90. Peghin M, Maiani M, Castaldo N, Givone F, Righi E, Lechiancole A, Sartor A, Pea F, Livi U, Bassetti M. Ceftolozane/tazobactam for the treatment of MDR Pseudomonas aeruginosa left ventricular assist device infection as a bridge to heart transplant. Infection. 2017;46:263–5.

    Article  PubMed  CAS  Google Scholar 

  91. Stokem K, Zuckerman JB, Nicolau DP, Wungwattana M, Sears EH. Use of ceftolozane-tazobactam in a cystic fibrosis patient with multidrug-resistant Pseudomonas infection and renal insufficiency. Respir Med Case Rep. 2018;23:8–9.

    PubMed  Google Scholar 

  92. Shields RK, Clancy CJ, Gillis LM, Kwak EJ, Silveira FP, Massih RCA, Eschenauer GA, Potoski BA, Nguyen MH. Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii Infections among solid organ transplant recipients. PLoS One. 2012;7(12):e52349. https://doi.org/10.1371/journal.pone.0052349.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Guo W, Sheng J, Gu Y, **ng T-H, Peng Z-H, Zhong L. Analysis and forecast for multidrug-resistant Acinetobacter baumannii Infections among liver transplant recipients. Transplant Proc. 2014;46:1448–52.

    Article  CAS  PubMed  Google Scholar 

  94. Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahma DF. In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant Gram-negative Bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 study). Antimicrob Agents Chemother. 2017. https://doi.org/10.1128/AAC.00093-17

  95. Hafkin J, Blumberg E. Infections in lung transplantation: new insights. Curr Opin Organ Transplant. 2009;14:483–7.

    Article  PubMed  Google Scholar 

  96. Alexander B, Petzold E. Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia cepacia complex. Transplant. 2008;8:1025–30.

    CAS  Google Scholar 

  97. Murray S, Charbeneau J, Marshall BC, LiPuma JJ. Impact of Burkholderia infection on lung transplantation in cystic fibrosis. Am J Respir Crit Care Med. 2008;178:363–71.

    Article  PubMed  Google Scholar 

  98. Boussaud V, Guillemain R, Grenet D, Coley N, Souilamas R, Bonnette P, Stern M. Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with Burkholderia cepacia complex: results from two French centres. Thorax. 2008;63:732–7.

    Article  CAS  PubMed  Google Scholar 

  99. Weill D. A consensus document for the selection of lung transplant candidates: 2014—an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Hear Lung Transplant. 2014;34:1–15.

    Google Scholar 

  100. Zhou J, Chen Y, Tabibi S, Alba L, Garber E, Saiman L. Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis. Antimicrob Agents Chemother. 2007;51:1085–8.

    Article  CAS  PubMed  Google Scholar 

  101. Papp-Wallace KM, Becka SA, Zeiser ET, et al. Overcoming an extremely drug resistant (XDR) pathogen: avibactam restores susceptibility to ceftazidime for Burkholderia cepacia complex isolates from cystic fibrosis patients. ACS Infect Dis. 2017;3:502–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Saiman L, Siegel J. Infection control in cystic fibrosis. Clin Microbiol Rev. 2004;17:57–71.

    Article  PubMed  PubMed Central  Google Scholar 

  103. O’Malley CA. Infection control in cystic fibrosis: cohorting, cross-contamination, and the respiratory therapist. Respir Care. 2009;54:641–57.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Meenakshi M. Rana

  2. Division of Infectious Diseases, University of Insubria, Varese, Italy

    Paolo Grossi

  3. Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Shirish Huprikar

Authors
  1. Meenakshi M. Rana
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paolo Grossi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shirish Huprikar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shirish Huprikar .

Editor information

Editors and Affiliations

  1. Infectious Diseases Service and Transplantation Center, University Hospital of Lausanne, Lausanne, Switzerland

    Oriol Manuel

  2. School of Medicine, Northwestern University Feinberg, Chicago, IL, USA

    Michael G Ison

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Rana, M.M., Grossi, P., Huprikar, S. (2019). Multidrug-Resistant Organisms in Solid Organ Transplantation. In: Manuel, O., Ison, M. (eds) Infectious Diseases in Solid-Organ Transplant Recipients. Springer, Cham. https://doi.org/10.1007/978-3-030-15394-6_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-15394-6_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-15393-9

  • Online ISBN: 978-3-030-15394-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation